OBI Ondine Biomedical Inc.

This Announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation No. 596/2014 as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018 as amended. Upon the publication of this Announcement, this inside information is now considered to be in the public domain.

All references to C$ in this announcement are to Canadian Dollars.

This Announcement assumes a £ : C$ exchange rate of 1 : 1.71690 and a £ : US$ exchange rate of 1 : 1.25155  as at 16:30 (GMT) on 1 May 2024.

2 May 2024

Ondine Biomedical Inc.

("Ondine" or the "Company")

Related Party Transactions

Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company, announces the following interim funding arrangements with related parties which were entered into in advance of a planned fundraising to extend working capital runway (the "Fundraising"), which was previously mentioned in the Company's announcement of 24 April 2024.

The Company is close to finalising arrangements for the Fundraising which will comprise a placing and a subscription (respectively, the "Placing" and the "Subscription"). The net proceeds of the Fundraising will be used for general working capital, US Phase 3 Clinical Trial readiness and start-up preparation, and to support the Company's rapid sales growth of its Steriwave® nasal decolonisation therapy. A further announcement is expected shortly in relation to the launch of the Fundraising.

Related Party Transactions

On 10 April 2024, substantial shareholder and CEO, Carolyn Cross, advanced a payment of US$160,000 (equivalent to £127,841) to the Company (the "Director Payment"), as a lead indication in the upcoming Fundraising as detailed above. In consideration, Carolyn Cross will be issued shares in the Subscription at the expected issue price on the same terms as all other participants in the Fundraising.

On 26 April 2024, Robert Cross, the husband of Carolyn Cross and substantial shareholder in the Company, advanced C$350,000 (equivalent to £203,856) to the Company (the "Related Party Loan"). The Related Party Loan accrues no interest, is unsecured and is expected to become repayable by mutual agreement between the lender and the Company upon completion of a subsequent fundraising or, at the sole discretion of the Company, may be repaid earlier.

Although not assessed at the time of entry into these arrangements, in aggregate the Director Payment and the Related Party Loan, are deemed to constitute related party transactions for the purpose of AIM Rule 13. Further disclosures are expected to be made shortly in relation to the Company's AIM Rule 13 obligations in respect of these transactions.

This Announcement is made in accordance with the Company's obligations under Article 17 of MAR and the persons responsible for arranging for the release of this Announcement on behalf of Ondine are Carolyn Cross, Chief Executive Officer and Nicolas Loebel, President and Chief Technical Officer of Ondine.   

Enquiries:

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader innovating light-activated antimicrobial therapies (also known as 'photodisinfection'). Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and the UK and is approved in Canada and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and many other indications.